摘要:
The present invention provides a compound represented by the formula wherein A represents (1) a bond, (2) a group represented by the formula —CRa═CRb— (Ra and Rb each represent a hydrogen atom or C1-6 alkyl) and the like; R1 represents (1) cyano or (2) an optionally esterified or amidated carboxyl group; R2 represents (1) a hydrogen atom, (2) an optionally substituted hydroxy group, (3) an optionally substituted amino group and the like; R3 and R4 each represent a hydrogen atom and the like; R5 represents a hydrogen atom and the like; R6 represents an optionally substituted hydroxy group and the like; R7 and R8 each represent an optionally substituted hydrocarbon group and the like; R9 and R10 each represent (1) a hydrogen atom and the like; Y represents an optionally substituted methylene group; and n represents 0 or 1, or a salt thereof, which has an excellent phosphodiesterase IV inhibiting action.
摘要翻译:本发明提供由下式表示的化合物:其中A表示(1)键,(2)由式-CR u> R a和R b各自表示氢原子或C 1-6烷基)等; R 1表示(1)氰基或(2)任选酯化或酰胺化的羧基; R 2表示(1)氢原子,(2)任选取代的羟基,(3)任选取代的氨基等; R 3和R 4各自表示氢原子等; R 5表示氢原子等; R 6表示任选取代的羟基等; R 7和R 8各自表示任选取代的烃基等; R 9和R 10各自表示(1)氢原子等; Y表示任选取代的亚甲基; n表示0或1,或其盐具有优异的磷酸二酯酶IV抑制作用。
摘要:
The present invention is directed to substituted 4H-chromenes and analogs thereof, represented by the Formula (I): wherein R1, R3-R5, A, D, Y and Z are defined herein. The present invention also relates to the discovery that compounds having Formula (I) are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
摘要:
Cosmetic or personal care compositions which comprise at least one fluorescent colorant other than white and at least one non-fluorescent colorant, are useful in preparing colored cosmetic or personal care preparations providing an enhanced skin appearance.
摘要:
The present invention provides a pharmaceutical composition which is useful as a phosphatidylinositol 3 kinase (PI3K) inhibitor and an antitumor agent, and it provides a novel bicyclic or tricyclic fused heteroaryl derivative or a salt thereof which possesses an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity.
摘要:
This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
摘要:
The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4—P-M-M4 I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
摘要翻译:本申请描述了含有内酰胺的化合物及其式I的衍生物:<?in-line-formula description =“In-line Formulas”end =“lead”→> P sub> 其中环P(如果存在的话)是5-7元碳环或其可药用盐形式,其中环P 杂环和环M是5-7元碳环或杂环。 本发明的化合物可用作胰蛋白酶样丝氨酸蛋白酶的抑制剂,特别是因子Xa。
摘要:
The invention relates a compound represented by the formula (1): Q1-Q2-C(═O)—N(R1)-Q3-N(R2)-T1-Q4 (1) wherein R1 and R2 represent H or the like; Q1 represents an aromatic ring, heterocyclic ring or the like; Q2 represents a single bond, aromatic ring, heterocyclic ring or the like; Q3 represents a group or the like, Q4 represents an aromatic ring, heterocyclic ring or the like; and T1 represents —CO— or —SO2—, and a medicine which comprises the compound and is useful for thrombosis and embolism.
摘要:
This invention provides novel arylindenopyridines and arylindenopyrimidines of the formula: wherein R1, R2, R3, R4, and X are as defined above, and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing adenosine A2a receptors. This invention also provides therapeutic and prophylactic methods using the instant compounds and pharmaceutical compositions.
摘要:
A simple and effective stereocontrolled synthesis of salinosporamide A (1) has been developed which follows the pathway outlined in the Figure. The process, the first total synthesis of salinosporamide A, is capable of providing the compound in substantial quantities for further biological studies. In addition to the method of Scheme I, the present invention also includes several novel synthetic intermediate compounds, several intermediate steps of the preferred synthetic process; and the uses of these compounds in the preparation of synthetic derivatives of the compound Salinosporamide A. Salinosporamide A is of special interest as a synthetic target because of its protein in vitro cytotoxic activity against many tumor cell lines (IC50 values of 10 nM or less).
摘要:
The invention provides compounds of Formula I: wherein Azabicyclo is These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which α7 is known to be involved.